Nutlin-3

製品コードS1061

Nutlin-3化学構造

分子量(MW):581.5

Nutlin-3は一種の有効で、選択性的なMdm2 (自身とp53に対するRING finger-dependent ubiquitin protein ligase) 拮抗剤で、無細胞試験でIC50値が90 nMですが、p53欠陥細胞中のp73を安定させられます。

サイズ 価格(税別)  
JPY 30710.00
JPY 18260.00
JPY 28220.00
JPY 61420.00
JPY 161020.00

カスタマーフィードバック(4)

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3は一種の有効で、選択性的なMdm2 (自身とp53に対するRING finger-dependent ubiquitin protein ligase) 拮抗剤で、無細胞試験でIC50値が90 nMですが、p53欠陥細胞中のp73を安定させられます。
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NEfFcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;kOeKh|ryP Ml;3OFjDqGh? MlnUZoxw[2u|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{ MYKyOlM2ODV4NR?=
NP69 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nFSWlEPTB;M{GuOlnDuTJwNUSg{txO MY[yOlI2OjV5NR?=
NP460 NImzcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrUN2ZTUUN3ME2yNk45PcLzMT6xPEDPxE1? NHrINpIzPjJ3MkW3OS=>
C666-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuweFBKSzVyPUG5Mlk2yrF6LkmzJO69VQ>? NV7i[|VDOjZ{NUK1O|U>
C666-1 M3;RNWNmdGxiVnnhZoltcXS7IFHzd4F6 MlrpNVAhyrWP MUe0PEBp NXHiXIw{TE2VTx?= M1;yNZNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIHPpd5Bt[XSrbh?= NXnwfoh[OjZ{NUK1O|U>
C666-1  M4rwRWZ2dmO2aX;uJGF{e2G7 MWCxNEDDvU1? NWHFUJBYOjRiaB?= NIfGdWZFVVOR MXHhZ5RqfmG2ZYOgeIhmKHB3MzDwZZRpf2G7LDD1dJJm\3WuYYTpcocheDV|LDDwNlEh[W6mIF3kcVI> MnHBNlYzPTJ3N{W=
C666-1 M1\JWWFxd3C2b4Ppd{BCe3OjeR?= MYixNEDDvU1? MmfMOFgwPzJiaB?= MV3EUXNQ MUHz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzDjbZNxdGG2aX6tbY5lfWOnZDDhdI9xfG:|aYO= MV6yOlI2OjV5NR?=
A549 NXXUN2h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MneyNlQhcA>? MWnJR|UxRTF5Lk[4JOKyKDRwNUKg{txO NYD0d2N[OjZzMkWyN|A>
A549-NTC M1rvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fueFI1KGh? NVjveWpGUUN3ME2xPU41OiEEsTCxMlk3KM7:TR?= NEW3coszPjF{NUKzNC=>
A549-920 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCyOEBp M1\MfWlEPTB;M{OuPFUhyrFiND64OEDPxE1? NHO1O3kzPjF{NUKzNC=>
CRL-5908 NXrBZ3k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fKVVI1KGh? NILzU4FKSzVyPUO4MlcyKMLzIEKuOFMh|ryP NEHZfYczPjF{NUKzNC=>
L6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPHU3QyOMLizszNxsA> NX3MWXBROjRxNEivO|IhcA>? NXX1N|NbTE2VTx?= NGXpXHdqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? MnzTNlU5PzF5OUS=
C2C12 NVXteY82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDqTHIyOMLizszNxsA> M{fkS|I1NzR6L{eyJIg> NVfnSFNrTE2VTx?= NVuzRWdJcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w NX65UWF3OjV6N{G3PVQ>
MCF-7  MVvGeY5kfGmxbjDBd5NigQ>? MkDINVDDqM7:TR?= NEHDV4hFVVOR MUXpcohq[mm2czDjfYNtcW5iREGgZY5lKESrY3XyxsA> NEiyepMzPTdyMkewNy=>
DU4475  MmPjSpVv[3Srb36gRZN{[Xl? NH;QNI82NzFyL{KwJO69VQ>? M3:wTFI1yqCq MkfX[I94dnKnZ4XsZZRmeyCWb3PhMVEh\G:|ZTDk[ZBmdmSnboTsfS=> NFLzSogzPTV2N{G3OC=>
SMMC-7721 MVvGeY5kfGmxbjDBd5NigQ>? M3fTelExKM7:TR?= NImxTXA1QCCq NH7RSHdFVVOR NUnVVnE3[2G3c3XzJGRPSSCGU1Kg[IFu[Wen Mlz2NlU2PDR|NkG=
SMMC-7721 MXXGeY5kfGmxbjDBd5NigQ>? NXjCZZBEOTBizszN M4LxTVQ5KGh? NGH1fnRFVVOR NVLHdFhNcW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>? NY\PbXlsOjV3NESzOlE>
SMMC-7721 MnrTSpVv[3Srb36gRZN{[Xl? NFLNS5QyOCEQvF2= NV;Uc3Y6PDhiaB?= NES1OmZFVVOR MoLCbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=> M{jRZVI2PTR2M{[x
SMMC-7721 M1Txe2Z2dmO2aX;uJGF{e2G7 M{nt[|ExKM7:TR?= MnjnN|YhcA>? NInjTHZFVVOR NUnGbG5j[2G3c3XzJJRp\SCnY4TvdIlkKGW6cILld5Nqd25ib3[gTWZKOTZ? NXPvSYdSOjV3NESzOlE>
MCF-7 M2TDZWZ2dmO2aX;uJGF{e2G7 NWrsXnNbOTEEoN88US=> MmrGNE0zPCCq M{W2N4lv\HWlZYOgdFU{KGGwZDDwNlEwS2myMR?= MljSNlU1QDJ|N{O=
OVCAR10 NWfob4lCTnWwY4Tpc44hSXO|YYm= NUnyV5dZOTEEoN88US=> MoGzNlFpyqB? MXzEUXNQ MUHpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MnnINlU1OjZ3NEi=
NCI-H23 NUmwdZRETnWwY4Tpc44hSXO|YYm= NEHSUFAyOMLizszN MV:yNYjDqA>? NUnFOHpOTE2VTx?= NIjvW2hqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ MXOyOVQzPjV2OB?=
A2780 M1fOPWZ2dmO2aX;uJGF{e2G7 M{H1S|ExyqEQvF2= NYfXOZlJOjGqwrC= MnTFSG1UVw>? NFjTVHNqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ MlTENlU1OjZ3NEi=
NCI-H23 NHLweG1HfW6ldHnvckBCe3OjeR?= NIXJ[mkyOMLizszN M1znZlIycMLi NVLpWI0yTE2VTx?= NWq1dWZG\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> M1jjeFI2PDJ4NUS4
A2780 NXjMfFlTTnWwY4Tpc44hSXO|YYm= MnHXNVDDqM7:TR?= NVLycYt5OjGqwrC= NWK3WnBbTE2VTx?= Mo\2[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= NX3BRYtZOjV2Mk[1OFg>
HCT116  M1n4WWZ2dmO2aX;uJGF{e2G7 NFTvWZIyOCEEtV2= NFi2NGQzPCCq MnvCZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 MmX6NlU{QDByNUW=
MCF-10CA1a MmWySpVv[3Srb36gRZN{[Xl? NXnVdHNtOTEEoN88US=> M4\2TlQ5KGh? M2DaWmROW09? NH[ySpBqdmirYnn0d{Bj[XOjbDDpcpZie2mxbjDhcoQhemWmdXPl[EBVT0ZvzsKzMYlv\HWlZXSgbY53[XOrb36geI8h[mG|YXygcIV3\Wy| NYTuUXdDOjV{NUe3Nlk>
MCF-10A1  NUD3cZhDTnWwY4Tpc44hSXO|YYm= NWK4fWlpOTEEoN88US=> Mk\qNlQwPDhiaB?= NGCyfnVFVVOR MoC3bY5pcWKrdIOgcYloemG2aX;uJI9nKG6xcn3hcEBjemWjc4Sg[ZBqfGinbHnhcOKh NXrCWZdROjV{NUe3Nlk>
MCF-10CA1a NGDFV3ZHfW6ldHnvckBCe3OjeR?= MnrUNVDDqM7:TR?= Mmm0NlQhcA>? MoPtSG1UVw>? Mk\y[IVkemWjc3XzJJRp\SCWR1[t{tI{NWmwZIXj[YQhdVKQQTDs[ZZmdHNib3\NUXAzNMLiTV3QPUwh[W6mwrDpcpRm\3KrbtMg{tLDqDN? MWCyOVI2Pzd{OR?=
MCF-10CA1a NVrxeHVXTnWwY4Tpc44hSXO|YYm= M4LYdFExyqEQvF2= MVqyOEBp NW\GXI1STE2VTx?= NWPxSIhzcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NFrITXMzPTJ3N{eyPS=>
SK-BR-7 MXTGeY5kfGmxbjDBd5NigQ>? NEPlTZYyOMLizszN NYLHVJNtOjRiaB?= NGj6WnlFVVOR MnX6bY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M{fPPVI2OjV5N{K5
SUM102PT NEG4XG5HfW6ldHnvckBCe3OjeR?= M3;OVlExyqEQvF2= M1zHSFI1KGh? MUXEUXNQ NX\4Sm5QcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u MXGyOVI2Pzd{OR?=
RAW 264.7 MoLYSpVv[3Srb36gRZN{[Xl? MnTLNVDDqM7:TR?= M{iwdVMxKG2rbh?= MmH5dJJmfmWwdIOgeIhmKHB3MzDy[YR2[3Srb36gbY4hemW|cH;ud4UhfG9iTGDT MX2yOVE4OjV2Nx?=
RAW 264.7 MnnoSpVv[3Srb36gRZN{[Xl? MYSxNOKh|ryP M3;iXVMxKG2rbh?= M1XTTZJm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= MnnKNlUyPzJ3NEe=
RAW 264.7 NH7SfJhHfW6ldHnvckBCe3OjeR?= NVHydFNoOTEEoN88US=> NG\lPVQ{OCCvaX6= MmDPbY5pcWKrdIOgUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbtMg M1L5OFI2OTd{NUS3
MCF7  M2jh[2NmdGxiVnnhZoltcXS7IFHzd4F6 NH\oTXYzNjViwsXN MXi1JIQ> MnvKSG1UVw>? M2TFUZNmdnOrdHn6[ZMhVUOINzD0c{BRSVKSIHnubIljcXSrb36= NWH3V2dPOjVyOEW5NFI>
MCF7  MmHMSpVv[3Srb36gRZN{[Xl? M1LySFIvPSEEtV2= M2i3SlQ5KGh? Mme5SG1UVw>? M2\HU4Rm[3KnYYPld{B1cGViaH;tc4xw\2:3czDEV2IhemWyYXnyJIZz\XG3ZX7jbYV{ M4fUfFI2ODh3OUCy
ACHN NET3T|lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVuwMlUuOTBizszN MlLyNE03KGR? M4rJXWROW09? M373NIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2DDZ|I2ODZ5N{i3
Caki-2 M3;DXmNmdGxiVnnhZoltcXS7IFHzd4F6 NUHnWFhiOC53LUGwJO69VQ>? M3vmWlAuPiCm NHnxeIxFVVOR M{jxN4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXyyOVA3Pzd6Nx?=
A498 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX[wMlUuOTBizszN MXWwMVYh\A>? M{jFSWROW09? NWXMPZBicW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlPPNlUxPjd5OEe=
115 M3zoW2NmdGxiVnnhZoltcXS7IFHzd4F6 NW\ZWY9QOC53LUGwJO69VQ>? M3PTRlAuPiCm NEjOPYJFVVOR MX\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEXlUGozPTB4N{e4Oy=>
117 MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVnjZnQ3OC53LUGwJO69VQ>? NHXqTHcxNTZiZB?= NVrUV3g6TE2VTx?= MkTQbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M17qNlI2ODZ5N{i3
ACHN M1zKO2Z2dmO2aX;uJGF{e2G7 MX2wMlUwOS93IN88US=> M{myc|Q5KGh? Mk\4SG1UVw>? NH:zdppt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NUXUU2Q2OjVyNke3PFc>
Caki-2 NIHHe4xHfW6ldHnvckBCe3OjeR?= NETsS4kxNjVxMT:1JO69VQ>? MX:0PEBp MkH5SG1UVw>? M4PLbIxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NHPvc|gzPTB4N{e4Oy=>
A498 MU\GeY5kfGmxbjDBd5NigQ>? NYnEcXNSOC53L{GvOUDPxE1? MYO0PEBp MWrEUXNQ NFjOS3Nt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= M{m5e|I2ODZ5N{i3
115 NF\lc4JHfW6ldHnvckBCe3OjeR?= MXuwMlUwOS93IN88US=> M33lTVQ5KGh? M1\wZmROW09? NW\u[lY5dGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= M1\1ZVI2ODZ5N{i3
ACHN M3LHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXy1JO69VQ>? NVLYSnA1PDhiaB?= NY\JVmZ4TE2VTx?= MYTpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NF64dlQzPTB4N{e4Oy=>
Caki-2 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rU[VUh|ryP NF;lXng1QCCq NWHWNpg5TE2VTx?= MWrpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NInRS28zPTB4N{e4Oy=>
A498 NH3XdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXe1JO69VQ>? M{LVb|Q5KGh? NXrIU5pVTE2VTx?= MkfYbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NI[wdZIzPTB4N{e4Oy=>
115 M2j3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTldVQ2KM7:TR?= M4freFQ5KGh? NXywVZJuTE2VTx?= NUjnT4M5cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh M2nKN|I2ODZ5N{i3
ACHN M2HHdWZ2dmO2aX;uJGF{e2G7 M1m1XFUh|ryP NVjxbWFIPDhiaB?= MUXEUXNQ MWPpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MX[yOVA3Pzd6Nx?=
Caki-2 NGDFd5RHfW6ldHnvckBCe3OjeR?= M1HmXlUh|ryP NY\S[Wg4PDhiaB?= Mm\PSG1UVw>? NH2zZohqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NFfXZoYzPTB4N{e4Oy=>
A498 MV;GeY5kfGmxbjDBd5NigQ>? Mn3ZOUDPxE1? NImx[m01QCCq M{LEOGROW09? NUDne4x4cW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> NVvo[JRwOjVyNke3PFc>
115 M{nTfWZ2dmO2aX;uJGF{e2G7 NIf6bII2KM7:TR?= NV7UVJBuPDhiaB?= NVHyUpdxTE2VTx?= MXXpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NFHid|UzPTB4N{e4Oy=>
MOLM-13 NFTLT5ZHfW6ldHnvckBCe3OjeR?= NFi0[oo3yqEQvF2= MUWwMVghcA>? Mmn6SG1UVw>? M{\YUYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIC1N{whVUSPMjygdFIyKGGwZDDhZ4V1gWyjdHXkJJA2Ow>? M4HpUFI1QDh3MEiy
MOLM-13 M{CwPGZ2dmO2aX;uJGF{e2G7 NI[2OWM3yqEQvF2= NEfWOXY3KGh? MX7EUXNQ M33ycIVvcGGwY3XzJJRp\SCjY3X0fYxifGmxbjDv[kBpcXO2b37lJGgzSiCjbnSgbIVifCC|aH;jb{Bxem:2ZXnud{BJe3B{NzDhcoQhUHOyOUC= NU\2[Xk4OjR6OEWwPFI>
HepG2 NHHXWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF25b244OiCq MUfEUXNQ MmTETWM2OD1|NT64OkDDuSB{Lkmg{txO MUWyOFg5PDhyOR?=
HepG2/As NYDtc21uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLTO|IhcA>? MUHEUXNQ M{C3RWlEPTB;NkiuNVMhyrFiOT62JO69VQ>? NY\ob4IyOjR6OES4NFk>
SMMC7721 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHRcZQ4OiCq MoLmSG1UVw>? MoK2TWM2OD1|MT6yPEDDuSB2LkKg{txO NH2yT3gzPDh6NEiwPS=>
SMMC7721/Ac MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPPSmw4OiCq MoHISG1UVw>? NIW4XWJKSzVyPUW1MlIyKMLzIEWuNFMh|ryP MlzCNlQ5QDR6MEm=
Huh-7 Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUO3NkBp MYLEUXNQ MkPUTWM2OD1|Mz65OkDDuSB|Lkmg{txO NUPNZ41OOjR6OES4NFk>
Hep3B MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf1O5FMPzJiaB?= MlXySG1UVw>? MWnJR|UxRTJyLkG4JOKyKDFwOESg{txO NGTmfo0zPDh6NEiwPS=>
HepG2 MXHBdI9xfG:|aYOgRZN{[Xl? NHL4cXlqdmS3Y3XzJIFxd3C2b4Ppdy=> MWWyOFg5PDhyOR?=
SMMC7721 M3\1V2Fxd3C2b4Ppd{BCe3OjeR?= MmXIbY5lfWOnczDhdI9xfG:|aYO= M3jPPVI1QDh2OEC5
Huh-7 M2W0TmFxd3C2b4Ppd{BCe3OjeR?= NHf1NXpqdmS3Y3XzJIFxd3C2b4Ppdy=> MV2yOFg5PDhyOR?=
Hep3B MmL3RZBweHSxc3nzJGF{e2G7 MnXzbY5lfWOnczDhdI9xfG:|aYO= NVTlOoZMOjR6OES4NFk>
U2OS  NGLVXINHfW6ldHnvckBCe3OjeR?= M4PrZlIxKM7:TR?= MYCyOEBp MnvGbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhSkOOMlGxMEBDS0y[TNMgZY5lSkOOVx?= M1;KclI1QDZ5MkW5
AML2 NGHac2lCeG:ydH;zbZMhSXO|YYm= MnHMNk8yOCEQvF2= MmrCNlQwPDhiaB?= MYrpcoR2[2W|IHHwc5B1d3Orcx?= NWHCe3lrOjR4NUm3OFk>
MOML13 NX;qdWIySXCxcITvd4l{KEG|c3H5 NUPncVVoOi9zMDFOwG0> Mk[1NlQwPDhiaB?= M4HJVolv\HWlZYOgZZBweHSxc3nz MV:yOFY2QTd2OR?=
AML2 NGLkbJRHfW6ldHnvckBCe3OjeR?= NX3nPIN4OTEQvF2= NH65eYIzNzRiaB?= MYjpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= Mlz6NlQ3PTl5NEm=
AML3 NWGxRYNQTnWwY4Tpc44hSXO|YYm= MnrGNVDPxE1? M{j4dVIwPCCq MoXpbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= MXmyOFY2QTd2OR?=
MOML13 MULGeY5kfGmxbjDBd5NigQ>? MY[xNO69VQ>? NYXpcnhYOi92IHi= NHi5OYlqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> MXSyOFY2QTd2OR?=
BeWo NI[2VmtHfW6ldHnvckBCe3OjeR?= NYLkRYh4OzBiwsXN NHjJZZkzPCCq MWDpcoNz\WG|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy= NV;RZXJ3OjR2OUixOVQ>
BeWo NXHFV202SXCxcITvd4l{KEG|c3H5 MnPKN|AhyrWP NUeyNJl3OjRiaB?= MWnpcoNz\WG|ZYOgZZBweHSxc3nz MW[yOFQ6QDF3NB?=
OCI NVrPTXg5TnWwY4Tpc44hSXO|YYm= NFLpVYoyOCEQvF2= MWKyOEBp M2DVbpVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= M37OUVI1PDd|NU[y
MOLM M3niTmZ2dmO2aX;uJGF{e2G7 NI\XV4MyOCEQvF2= MUWyOEBp MVr1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? M33tUFI1PDd|NU[y
U2OS  MmjKSpVv[3Srb36gRZN{[Xl? MX2yNEDPxE1? MVmyOEBp NFTwdlZqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw MmPHNlQ{PjZyMEe=
RKO NFPSV45HfW6ldHnvckBCe3OjeR?= MkPwNlAh|ryP MnnyNlQhcA>? MXjpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv M4DHfVI1OzZ4MEC3
U2OS  NGPHbmpHfW6ldHnvckBCe3OjeR?= NE[wemwzOCEQvF2= Mlr3NlQhcA>? MWTpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= NEHWbnczPDN4NkCwOy=>
RKO NUXZTXNYTnWwY4Tpc44hSXO|YYm= NGHmVW4zOCEQvF2= MYCyOEBp MoWybY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MoixNlQ{PjZyMEe=
SMMC-7721  NX7ERWE6S2WubDDWbYFjcWyrdImgRZN{[Xl? NVHUNnVsOS5{NT2yNEDPxE1? NWLjflZnOjRxNEivO|IhcA>? NUXuWWF4TE2VTx?= NEi4fYhqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MX2yOFI5PjNzMh?=
HuH-7 NHzsPXlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXGxMlI2NTJyIN88US=> M3XQT|I1NzR6L{eyJIg> NILY[49FVVOR M1H6VolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 NGn2UVEzPDJ6NkOxNi=>
SMMC-7721  NXjo[oRFSXCxcITvd4l{KEG|c3H5 MnnBNlAh|ryP M4jzblQ5KGh? MUHEUXNQ M3PXeolv\HWlZYOgZZBweHSxc3nz M{n3W|I1Ojh4M{Gy
HuH-7 MmXORZBweHSxc3nzJGF{e2G7 NHT6OGgzOCEQvF2= NXPxUo1PPDhiaB?= M4nDTmROW09? NIXiW5lqdmS3Y3XzJIFxd3C2b4Ppdy=> NUjZVFZZOjR{OE[zNVI>
SMMC-7721  M3m5WmZ2dmO2aX;uJGF{e2G7 MmjHNVAh|ryP MVGzOkBp NGTyfm5FVVOR M{[5Z4Rwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ MX6yOFI5PjNzMh?=
HuH-7 MUDGeY5kfGmxbjDBd5NigQ>? MnLZNVAh|ryP MYqzOkBp M3PFTmROW09? MkD1[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> MmLjNlQzQDZ|MUK=
AT2 NF35bWFHfW6ldHnvckBCe3OjeR?= MWO1M|ExKM7:TR?= NYDOOVJ4dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MYSyOFI1ODJyMx?=
REH M2DwXmZ2dmO2aX;uJGF{e2G7 NW\PUnI2PS9zMDFOwG0> NX74NYRqdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= NXzucY9lOjR{NECyNFM>
UoCB6 NXfibFVLTnWwY4Tpc44hSXO|YYm= MknVOU8yOCEQvF2= NHrnOHdt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= NHrLcVIzPDJ2MEKwNy=>
AT2 NWr1cGsxS2WubDDWbYFjcWyrdImgRZN{[Xl? NGXhdGcxNTJ3IN88US=> NWPyNGpQcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M3r6U|I1OjRyMkCz
REH NIjydpNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGPY[|ExNTJ3IN88US=> Mn23bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M3vxNFI1OjRyMkCz
UoCB6 Ml3IR4VtdCCYaXHibYxqfHliQYPzZZk> NFTWRo4xNTJ3IN88US=> MkW1bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M3H5WVI1OjRyMkCz
A2780 NH[0RlBHfW6ldHnvckBCe3OjeR?= M2TCelUwOTBxMkCg{txO NX3XflB1OjRiaB?= NFnCZo12eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= NFLWeHczPDF|NkG0Oy=>
H460 MXfGeY5kfGmxbjDBd5NigQ>? M1zwb|UwOTBxMkCg{txO NWX5NJJmOjRiaB?= MX\1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? M1PzR|I1OTN4MUS3
Lovo  NHz6SpBHfW6ldHnvckBCe3OjeR?= NX7aSJg{PS9zMD:yNEDPxE1? MlHKNlQhcA>? NISx[nV2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MW[yOFE{PjF2Nx?=
A2780 NY\KNVZ1SXCxcITvd4l{KEG|c3H5 M1O2[|UwOTBxMkCg{txO MWOyOEBp MWflcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> M12wZlI1OTN4MUS3
H460 MUnBdI9xfG:|aYOgRZN{[Xl? Ml7hOU8yOC9{MDFOwG0> NF;DVW0zPCCq MmHr[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> MVWyOFE{PjF2Nx?=
Lovo  MmrBRZBweHSxc3nzJGF{e2G7 M{DlV|UwOTBxMkCg{txO MYOyOEBp NUTJNllZ\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M3\iT|I1OTN4MUS3

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験:

[1]

+ 展開
  • 細胞株: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度: Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間: 8, 24, and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 製剤: Formulated in 2% Klucel, 0.5% Tween 80
  • 投薬量: 200 mg/kg
  • 投与方法: Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4

CAS No. 890090-75-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Related Antibodies

Mdm2信号経路図

相関Mdm2製品

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID